Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
PLoS One. 2013;8(4):e59658. doi: 10.1371/journal.pone.0059658. Epub 2013 Apr 3.
The aim of the present work was to test the potential of Proton Transfer Reaction Time-of-Flight Mass Spectrometry (PTR-ToF-MS) in the diagnosis of liver cirrhosis and the assessment of disease severity by direct analysis of exhaled breath. Twenty-six volunteers have been enrolled in this study: 12 patients (M/F 8/4, mean age 70.5 years, min-max 42-80 years) with liver cirrhosis of different etiologies and at different severity of disease and 14 healthy subjects (M/F 5/9, mean age 52.3 years, min-max 35-77 years). Real time breath analysis was performed on fasting subjects using a buffered end-tidal on-line sampler directly coupled to a PTR-ToF-MS. Twelve volatile organic compounds (VOCs) resulted significantly differently in cirrhotic patients (CP) compared to healthy controls (CTRL): four ketones (2-butanone, 2- or 3- pentanone, C8-ketone, C9-ketone), two terpenes (monoterpene, monoterpene related), four sulphur or nitrogen compounds (sulfoxide-compound, S-compound, NS-compound, N-compound) and two alcohols (heptadienol, methanol). Seven VOCs (2-butanone, C8-ketone, a monoterpene, 2,4-heptadienol and three compounds containing N, S or NS) resulted significantly differently in compensate cirrhotic patients (Child-Pugh A; CP-A) and decompensated cirrhotic subjects (Child-Pugh B+C; CP-B+C). ROC (Receiver Operating Characteristic) analysis was performed considering three contrast groups: CP vs CTRL, CP-A vs CTRL and CP-A vs CP-B+C. In these comparisons monoterpene and N-compound showed the best diagnostic performance.
Breath analysis by PTR-ToF-MS was able to distinguish cirrhotic patients from healthy subjects and to discriminate those with well compensated liver disease from those at more advanced severity stage. A breath-print of liver cirrhosis was assessed for the first time.
本研究旨在通过直接分析呼出气,检测质子转移反应飞行时间质谱(PTR-ToF-MS)在诊断肝硬化和评估疾病严重程度方面的潜力。方法:共纳入 26 名志愿者,其中 12 名肝硬化患者(男/女 8/4,平均年龄 70.5 岁,42-80 岁),14 名健康对照者(男/女 5/9,平均年龄 52.3 岁,35-77 岁)。空腹状态下,使用缓冲的末端呼气流在线采样器直接与 PTR-ToF-MS 相连,对受试者进行实时呼出气分析。结果:与健康对照组(CTRL)相比,肝硬化患者(CP)呼出的 12 种挥发性有机化合物(VOCs)显著不同:4 种酮类(2-丁酮、2-或 3-戊酮、C8-酮、C9-酮)、2 种萜烯(单萜、单萜相关)、4 种含硫或氮的化合物(亚砜化合物、S 化合物、NS 化合物、N 化合物)和 2 种醇类(庚二烯醇、甲醇)。在代偿期肝硬化患者(Child-Pugh A;CP-A)和失代偿期肝硬化患者(Child-Pugh B+C;CP-B+C)中,7 种 VOCs(2-丁酮、C8-酮、单萜、2,4-庚二烯醇和 3 种含 N、S 或 NS 的化合物)存在显著差异。采用受试者工作特征(ROC)曲线分析了 3 种对比组:CP 与 CTRL、CP-A 与 CTRL、CP-A 与 CP-B+C。在这些比较中,单萜和 N 化合物显示出最佳的诊断性能。结论:PTR-ToF-MS 呼气分析能够区分肝硬化患者和健康受试者,并区分肝功能代偿良好的患者和病情更严重的患者。首次评估了肝硬化的呼气特征。